| Stereochemistry | RACEMIC |
| Molecular Formula | C10H15NO |
| Molecular Weight | 165.2322 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN[C@H](C)[C@@H](O)C1=CC=CC=C1
InChI
InChIKey=KWGRBVOPPLSCSI-PSASIEDQSA-N
InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m1/s1
| Molecular Formula | C10H15NO |
| Molecular Weight | 165.2322 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Racephedrine in combination with theophylline, phenobarbital was used to treat bronchial asthma. However, its application was substituted more effective agent. In addition, FDA has reviewed the final monograph for over-the-counter bronchodilator drug products to add additional warnings and to revise the indications in the labeling of products containing racephedrine hydrochloride.
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
